Seminar programme

Programme: New Horizons in Biologics & Bioprocessing

Copenhagen, May 28th
 

Note that changes to the programme may occur. Any changes will be reflected here. Stay up to date by revisiting this page before the event.


 

08.30                Registration, 1-2-1 meetings & networking in the exhibition hall

09.00                Welcome and introduction

                                 Morten Munk, Director Global Alliance Management, FUJIFILM Diosynth Biotechnologies

09.05                Gene therapy: Cure for the patient – curse for the manufacturer?

                                Johan Rockberg, Professor in Antibody Technology and Directed Evolution, KTH Royal Institute of Technology

09.30                Medicine of the future

                                Cecilia Norling, MSc in Medical Biology, Quality Assurance Manager, VERIGRAFT

09.55                Coffee, 1-2-1 meetings & networking in the exhibition hall

10.35                A highly efficacious vaccine against malaria – why is it so difficult?

                                Kristina Persson, Associate Professor, Senior Lecturer, Lund University, and

                                Senior Consultant, Laboratory Medicine, Lund University Hospital

11.00                Preclinical proof of concept for a novel VLP-based vaccine candidate for treatment of HER2+ breast cancer

                                Max Søgaard, Senior VP R&D and Technology, ExpreS2ion Biotechnologies

11.25                Xbrane and the development of high quality biosimilars

                                David Vikström, Chief Technology Officer, Xbrane Biopharma

11.50                Lunch, 1-2-1 meetings & networking in the exhibition hall

12.50                A novel in-line sensor system for real-time bioprocess monitoring

                                Erik Martinsson, CEO and Co-founder, ArgusEye

13.15                Fermentation harvest modalities using single use centrifuges

                                Peter Thorwid, Concepts Manager, Business Unit High Speed Separators, Alfa Laval

                                Pontus Linderholm, R&D Manager Single-Use, Business Unit High Speed Separators, Alfa Laval

13.40                Cellevat3dTM microcarriers - The 1st nanofiber-based microcarriers designed for viral vector biomanufacturing

                                Laura Chirica, PhD, CEO, Cellevate

14.05                Coffee, 1-2-1 meetings & networking in the exhibition hall

14.45                Is our industry really industrialised? – Industrialising biologics to dramatically improve patient access with the modular kojoX approach

                                Rasmus Pedersen, Senior Modularity Architect, FUJIFILM Diosynth Biotechnologies

15.10                Boosting the speed of Genmab's CMC timelines for antibody products

                                Jesper Valbjørn, Senior Vice President, Head of Global CMC Operations, Genmab

15.35                Summary & conclusion
~15.40                 Morten Munk, Director Global Alliance Management, FUJIFILM Diosynth Biotechnologies